Luca Visani retweeted
Proud of @LucaVisani2 and our Florence team presenting this poster on behalf of an international consortium - brand new data on combining sacituzumab govitecan with #radiotherapy in #breastcancer
Much more to come! #ESMO26
#OncoAlert @OncoAlert @AOUCareggi @UNI_FIRENZE
Luca Visani retweeted
Amazing and timely keynote by Prof. @reshmajagsi on equity, culture, leadership and patient-centred care.
50 shades of disparity around the world 🌎
Closing session #FlorenceConsensus26
@OncoAlert @ESTRO_RT #OncoAlert #Oncology
Luca Visani retweeted
Good news to start the year. In a RW cohort of 67 patients receiving concomitant T-DXd and RT (within 10 days - 55% brain), the risk of AEs or discontinuation was comparable to patients not receiving RT. Only one case of symptomatic radionecrosis (1.5%). thebreastonline.com/article/…
Luca Visani retweeted
ASCENT-03 support sacituzumab govitecan (SG) as a potential new standard for previously untreated mTNBC not candidate for a PDL1 inhibitor
#ESMO25 @OncoAlert #OncoAlert
And another @NEJM publication 💪🏼
@JavierCortesMD
Luca Visani retweeted
DESTINY-Breast05 investigators deserve congratulations once again - for collecting data on sequential and concurrent RT with T-DXd vs T-DM1, including CT imaging and ILD/pneumonitis quality data
Concomitant treatment safe
#ESMO25 @OncoAlert #OncoAlert #BreastCancer #radonc
Luca Visani retweeted
TROPION-Breast02 met both primary endpoints OS and PFS in mTNBC (immunotherapy not an option) in favour of Dato-DXd #ESMO25
@OncoAlert #OncoAlert
Luca Visani retweeted
Welcome back @myESMO #ESTRO25
Stronger, together 💪
👉 Chairing with @curijoey ESMO President Elect - the ESTRO-ESMO Symposium on Integration of Novel Systemic Therapies into #Radiotherapy (3 May 2025)
bit.ly/3UNMfqo
@ESTRO_RT @OncoAlert #OncoAlert #medonc #radonc
👉 Join us for the ESTRO-ESMO Symposium: Integration of Novel Systemic Therapies into Radiotherapy
📅 Saturday, 3 May 2025
Vienna, Austria
Chaired by:
👨⚕️ Giuseppe Curigliano (Italy)
👨⚕️ Icro Meattini (Italy)
🔗 : bit.ly/4f1Phzw
📄 : bit.ly/3UNMfqo
#Radonc
Esclusive RT vs ET for older women >70y with pT1N0 luminal A tumors. Less impact on HRQoL with RT at the first interim analysis. Wonderful presentation by @Icro_Meattini, very well done! Proud to be part of this project. See the concomitant publication on Lancet Oncology! #SABCS
Luca Visani retweeted
Association between risk reducing surgeries and survival in young BRCA carriers with #BreastCancer
Accumulating crucial evidence presented by amazing Prof Matteo Lambertini #SABCS24 @matteolambe
@OncoAlert #OncoAlert
EMBER-3: imlunestrant alone or imlunestrant plus abemaciclib vs fulvestrant in patients previously treated with ET (prior CDK4/6i in 60% of patients). Imlunestrant effective as monotherapy in ESR1m patients, in combination with abema benefit showed for all patients #SABCS24
1
112
Luca Visani retweeted
Great @EORTC_BCG Autumn Meeting in Paris @institut_curie ! 2 days of insightful presentations and productive discussions on current and future activities of the group! @MIgnatiadis @EtienneB66 @c_sotiriou @EORTC @OncoAlert #breastcancer #bcsm
Luca Visani retweeted
Very Happy to present early results from STARR trial (NCT05455736) at ASTRO! #ASTRO24 ,@dicataldovanes1 ,@PietroGarlatti
Multicentre retrospective study comparing safety outcomes of BC patients treated with T-DXd with or without concomitant RT (379P). No impact on acute toxicity development and T-DXd discontinuation ‼️@Icro_Meattini @i_ratosa @CarlottaB @VSalvestrini @andMORand #ESMO2024 #ESMO24
Luca Visani retweeted
Neoadjuvant pembrolizumab or placebo plus chemotherapy for triple negative #breastcancer - Overall Survival results from the KEYNOTE-522 phase 3 trial #ESMO24
@NEJM @myESMO
#OncoAlert @OncoAlert
Luca Visani retweeted
#esmo2024 Meghna Trivedi presents results from I-SPY2.2 Dato-DXd plus Durva. This personalized approach to therapy allows optimal efficacy with reduced toxicity in 50% with most achieving pCR without anthracyclines. Imp model for trials @OncoAlert
Another important confirmation that ER-low breast cancer should be treated as triple negative! #ESMO2024 #ESMO24 #breastcancer
Luca Visani retweeted
Registry of stage 1 TNBC (>1100 pts)
pCR: 57.3%
pCR associated w/ better OS (HR 0.29)
@OncoAlert #bcsm #ESMO24
Magnitude of benefit in iDFS with adjuvant ribociclib plus NSAI seems to be higher for younger patients. #ESMO2024 #ESMO24 #breastcancer
1
75
Confirmed importance of ovarian suppression (especially plus AI) for premenopausal HR+/HER2+ patients, irrespectively of adjuvant trastuzumab administration in the HERA trial #ESMO2024 #ESMO24 #breastcancer
1
76
Luca Visani retweeted
PERSIAN trial will offer the unique opportunity to evaluate SBRT in a selected cohort of oligometastatic metachronous patients. It reached 30% of planned accrual! @dicataldovanes1,@PietroGarlatti,@ALESSIOBRUNI10
acrobat.adobe.com/id/urn:aai…























































